GIST label for Novartis' Glivec expanded to three years in Europe
This article was originally published in Scrip
Executive Summary
The European Commission has approved an update to the label for Novartis' Glivec/Gleevec (imatinib) to include three years of treatment after surgery for adults with KIT (CD117)-positive gastrointestinal stromal tumours (GIST).